A Review of Progress on Targeting LDL Receptor-Dependent and -Independent Pathways for the Treatment of Hypercholesterolemia, a Major Risk Factor of ASCVD
Since the discovery of the LDL receptor in 1973 by Brown and Goldstein as a causative protein in hypercholesterolemia, tremendous amounts of effort have gone into finding ways to manage high LDL cholesterol in familial hypercholesterolemic (HoFH and HeFH) individuals with loss-of-function mutations...
Main Author: | Rai Ajit K. Srivastava |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-06-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/12/12/1648 |
Similar Items
-
PCSK9: BIOLOGICAL ACTIVITY REGULATION AND CONNECTION WITH LIPID AND CARBOHYDRATE METABOLISM
by: A O Averkova
Published: (2017-09-01) -
Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
by: Piotr Pęczek, et al.
Published: (2021-05-01) -
Competing Genetic Traits and Their Influence on LDL Cholesterol Concentration in Familial Hypercholesterolemia
by: Christopher Song, MD, et al.
Published: (2024-01-01) -
Hypercholesterolemia - non-pharmacological treatment, monotherapy or combination therapy. Review of the literature
by: Weronika Łowicka, et al.
Published: (2024-08-01) -
MiR-99a-5p up-regulates LDLR and functionally enhances LDL-C uptake via suppressing PCSK9 expression in human hepatocytes
by: Xuemei Chen, et al.
Published: (2024-11-01)